Showing 1561-1570 of 2656 results for "".
- China’s NMPA Accepts NDA for IBI-305, a Biosimilar Product Candidate of Bevacizumab (Avastin)https://modernod.com/news/chinas-nmpa-accepts-nda-for-ibi-305-a-biosimilar-product-candidate-of-bevacizumab-avastin/2479596/Innovent Biologics announced that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for a biosimilar product candidate of bevacizumab (Avastin). This NDA by Innovent is the third that has been accepted by the NMPA following Tyvyt (sintilimab injectio
- Riata Capital’s Acuity Eyecare Group Completes Acquisitions in Colorado and Nebraskahttps://modernod.com/news/riata-capitals-acuity-eyecare-group-completes-acquisitions-in-colorado-and-nebraska/2476208/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of leading North American eyecare groups and optometry practices, has acquired two new regional eyecare groups, totaling 18 locations: ABBA Eye Care, based in Colorado Springs, Colora
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- Wills Eye Hospital’s Training in Ophthalmology Voted #1 Top Eye Residency Program in Nationhttps://modernod.com/news/wills-eye-hospitals-training-in-ophthalmology-voted-1-top-eye-residency-program-in-nation/2479623/The Wills Eye at Jefferson Residency Program in Philadelphia has been voted the #1 medical education training program in ophthalmology in the nation, according to Doximity.com. The Wills Eye Hospital faculty serve as the department of Ophthalmology at Thomas Jefferson
- Anthem Blue Cross Blue Shield Now Covering Avedro’s Corneal Cross-Linking Procedurehttps://modernod.com/news/anthem-blue-cross-blue-shield-now-covering-avedros-corneal-cross-linking-procedure/2479624/Avedro announced that Anthem, the largest member of the Blue Cross Blue Shield Association, has issued a positive coverage policy for Avedro’s FDA-approved corneal cross-linking procedure bringing the total number of
- Acuvue Oasys with Transitions Light Intelligent Technology Named Among TIME’s ‘Best Inventions of 2018’https://modernod.com/news/acuvue-oasys-with-transitions-light-intelligent-technology-named-among-times-best-inventions-of-2018/2479661/TIME has selected Acuvue Oasys with Transitions Light Intelligent Technology as one of the ‘Best Inventions of 2018,’ in its annual round-up spotlighting groundbreaking innovations worldwide. The development of Acuvue Oasys with Transitions has created and defined an entirely new cate
- Clearside Biomedical’s Combination Therapy in RVO Does Not Meet Primary Endpoint in Phase 3 Trialhttps://modernod.com/news/clearside-biomedicals-combination-therapy-in-rvo-does-not-meet-its-primary-endpoint-in-phase-3-trial/2479701/Clearside Biomedical announced that the primary endpoint was not achieved in its phase 3 clinical trial (SAPPHIRE) investigating the superiority of XIPERE (formerly suprachoroidal CLS-TA) used together with the intravitreal anti-VEGF agent Eylea (aflibercept), compared to intravit
- Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Diseasehttps://modernod.com/news/optos-and-amydis-establish-clinical-alliance-to-develop-early-diagnostic-test-for-alzheimers-disease/2479754/Optos, a subsidiary of Nikon Corporation, and Amydis announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ optomap ultra-wi
- Sun Pharma’s Dry Eye Disease Treatment Cequa Approved by the FDAhttps://modernod.com/news/sun-pharma-announces-fda-approval-of-cequa-to-treat-dry-eye-disease/2479938/There is a new pharmacological option for dry eye disease as Sun Pharma received FDA approval for Cequa (cyclosporine ophthalmic solution 0.09%). Cequa, which is indicated to increase tear production in patients with dry eye, provides the highest FDA-approved concentration of cyclosporine
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio